Objective: To find out the relationship between hematological parameters and disease severity among COVID-19 patients. Methods: This cross-sectional analytical study was conducted in the COVID unit of Dhaka Medical College and Hospital (DMCH). The study was conducted from October 2020 to September 2021. Patients diagnosed with COVID-19 infection detected by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) admitting in the Corona unit of DMCH, Dhaka, Bangladesh. Purposive sampling technique was applied to collect the samples. 96 patients were included for the study. Result: In case of severity of patients, 17 (17.7%) patients had mild illness, 29 (30.2%) had moderate illness and 50 (52.1%) patients had severe illness due to COVID-19 infection. Furthermore, according to gender, the proportion of male patients (70.0%) were significantly more in severe group compared to mild/moderate group (47.8%). Moreover, the mean age of the patients in severe group (56.2± 14.3) were significantly higher than the mean age of the patients in mild/moderate group (48.7±12.5) as p=0.007. Patients in severe group had significantly higher neutrophil count than mild/moderate group (p<0.001). On the other hand, patients in severe group had significantly lower lymphocyte, eosinophil and platelet count than mild/moderate group (p<0.05). The neutrophil-to-lymphocyte ratio (NLR) was significantly higher in severe group compared to mild/moderate group (p<0.001).

The purpose of the present study was to find out the clinicopathological characteristics of Hepatocellular Carcinoma (HCC) patients. All the clinically suspected patients were recruited as per inclusion and exclusion criteria. The relevant socio-demographic characteristics, clinical findings as well as the physical examination were performed after talking written consent from all the study subjects. The ultrasonography was performed to all the patients. After that, the patients were sent to the department of pathology for histopathological examination. The descriptive cross-sectional study was carried out in the Department of Oncology of National Institute of Cancer Research and Hospital (NICRH), Dhaka, Bangladesh from July 2014 to June 2015 for a period of 12 months. Total sample size was 52 in this study and age distribution of HCC was found from 25 years to 97 years to with the mean age 50.57 ± 12.09 years. Males were predominant (78.0%), male and female ratio was 3.72:1. The common presenting features of HCC were abdominal pain and swelling, fever and jaundice; viral marker was positive in 86.5% of patients (HBsAg-67.3%, Anti HCV-19.2%) with normal tumor marker alpha-fetoprotein (AFP) in 69% of the patients. Okuda staging shows 82.7% patients within stage I and Stage II and performance status, 38.5% patients were unable to carry out normal activity. Sonological findings revealed 69.2% patients had ≤2 cm tumor size, 88.4% had ascites lastly splenomegaly was present among 86.5% respondents.

Objectives: Breast cancer is the most common malignant tumor of females; the incidence increases with age. Bone is the most common site to which breast cancer metastasizes. Between 30% to 85% of patients with metastatic breast cancer develop bone metastases during the course of the disease. Carbohydrate antigen (CA) 15-3 is a circulating human breast cancer associated antigen used as a tumor marker in the screening of breast cancer patients for metastasis. The objective of this study was to compare the levels of CA 15-3 and bone scan findings in patients with breast cancer. Material and Methods: This cross-sectional analytical study was carried out at Rajshahi medical college hospital, Rajshahi, from January 2018 to December 2019. A total of 90 diagnosed breast cancer patients were enrolled in this study. Among them 45 patient was with normal CA 15-3 level and 45 patient was with elevated CA 15-3 level. All of them underwent bone scan. The tumor maker CA 15-3 was compared with bone scan findings. Results: Mean age of the patients was 46.62 ± 8.67 years (range 33 to 67 years). Among 45 patients with normal CA 15-3 level, bone scan was negative for metastasis in 39 (86.66%) patients with CA 15-3 level 14.96 ± 9.72U/ml and positive for metastasis in 6 (13.33%) patient with CA 15-3 level 23.3 ± 2.96U/ml. Out of 45 patients with elevated CA 15-3 level 11 (24.44%) had negative bone scan with CA 15-3 level 92.5 ± 19.89 U/ml whereas 34 (75.55%) patient had positive bone scan findings with CA 15-3 level 413.83 ± 362.83U/ml. In current study, Pearson’s correlation coefficient test showed positive relation, for elevated CA 15-3 level and Bone scan findings there was (r = 0.853, p = 0.00001) and for normal CA15-3 level and bone scan finding (r = 0.449, p = 0. 0019). Conclusion: The result of this study showed positive relationship between the bone scan findings and CA 15-3 level of breast carcinoma patients.